載入...

p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer

Bevacizumab, an antibody to vascular endothelial growth factor (VEGF), has been incorporated into chemotherapy regimens in the treatment of several cancer types including breast cancer. The aim of this study was to identify tumor and angiogenic factors that potentially associate with outcome. In a p...

全面介紹

Na minha lista:
書目詳細資料
發表在:Int J Oncol
Main Authors: YANG, SHERRY X., STEINBERG, SETH M., NGUYEN, DAT, SWAIN, SANDRA M.
格式: Artigo
語言:Inglês
出版: 2011
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7316373/
https://ncbi.nlm.nih.gov/pubmed/21399868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2011.966
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!